New drug cures Hepatitis C in HIV patients

In a ray of hope for patients infected with both HIV and Hepatitis C, researchers have found that a combination drug therapy cures chronic Hepatitis C in majority of such patients.

Hepatitis C is a leading cause of death among HIV co-infected patients.

"Because of poor tolerability to the previous standard of treatments for Hepatitis C, co-infection patients were considered difficult to treat," said Mark Sulkowski, medical director of the Johns Hopkins Infectious Disease Centre for Viral Hepatitis.

Now, the data from a Phase III clinical trial have been incorporated into the US Food and Drug Administration's (FDA) approval of the new drug called sofosbuvir.

"The treatment with a new all-oral regimen - sofosbuvir and ribavirin - is now considered on-label," researchers reported.

For the trial, doctors administered sofosbuvir and ribavirin to a total of 223 HIV-1 patients chronically co-infected with Hepatitis C either for 12 weeks.

Twelve weeks after the treatment ended, researchers tested patients again for Hepatitis C infection to determine if the treatment was effective.

They found that 76 percent patients with genotype 1, 88 percent with genotype 2 and 67 percent with genotype 3 were cured.

"We have always termed this to be 'sustained virologic response but we now know that means hepatitis C has been cured," Sulkowski noted.

The trial study was published in the Journal of the American Medical Association.

image
Business Standard
177 22
Business Standard

New drug cures Hepatitis C in HIV patients

IANS  |  Washington 

In a ray of hope for patients infected with both HIV and Hepatitis C, researchers have found that a combination drug therapy cures chronic Hepatitis C in majority of such patients.

Hepatitis C is a leading cause of death among HIV co-infected patients.

"Because of poor tolerability to the previous standard of treatments for Hepatitis C, co-infection patients were considered difficult to treat," said Mark Sulkowski, medical director of the Johns Hopkins Infectious Disease Centre for Viral Hepatitis.

Now, the data from a Phase III clinical trial have been incorporated into the US Food and Drug Administration's (FDA) approval of the new drug called sofosbuvir.

"The treatment with a new all-oral regimen - sofosbuvir and ribavirin - is now considered on-label," researchers reported.

For the trial, doctors administered sofosbuvir and ribavirin to a total of 223 HIV-1 patients chronically co-infected with Hepatitis C either for 12 weeks.

Twelve weeks after the treatment ended, researchers tested patients again for Hepatitis C infection to determine if the treatment was effective.

They found that 76 percent patients with genotype 1, 88 percent with genotype 2 and 67 percent with genotype 3 were cured.

"We have always termed this to be 'sustained virologic response but we now know that means hepatitis C has been cured," Sulkowski noted.

The trial study was published in the Journal of the American Medical Association.

RECOMMENDED FOR YOU

New drug cures Hepatitis C in HIV patients

In a ray of hope for patients infected with both HIV and Hepatitis C, researchers have found that a combination drug therapy cures chronic Hepatitis C in majority of such patients.

In a ray of hope for patients infected with both HIV and Hepatitis C, researchers have found that a combination drug therapy cures chronic Hepatitis C in majority of such patients.

Hepatitis C is a leading cause of death among HIV co-infected patients.

"Because of poor tolerability to the previous standard of treatments for Hepatitis C, co-infection patients were considered difficult to treat," said Mark Sulkowski, medical director of the Johns Hopkins Infectious Disease Centre for Viral Hepatitis.

Now, the data from a Phase III clinical trial have been incorporated into the US Food and Drug Administration's (FDA) approval of the new drug called sofosbuvir.

"The treatment with a new all-oral regimen - sofosbuvir and ribavirin - is now considered on-label," researchers reported.

For the trial, doctors administered sofosbuvir and ribavirin to a total of 223 HIV-1 patients chronically co-infected with Hepatitis C either for 12 weeks.

Twelve weeks after the treatment ended, researchers tested patients again for Hepatitis C infection to determine if the treatment was effective.

They found that 76 percent patients with genotype 1, 88 percent with genotype 2 and 67 percent with genotype 3 were cured.

"We have always termed this to be 'sustained virologic response but we now know that means hepatitis C has been cured," Sulkowski noted.

The trial study was published in the Journal of the American Medical Association.

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard